NCT04570475终止不适用
High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache: a Randomized, Double-blind, Placebo Controlled Trial.
The University of Texas Health Science Center, Houston2 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2021年9月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 2
- 主要终点
- Change in average weekly frequency of cluster headache attacks
研究概览
简要总结
This study intends to investigate the use of high-dose Vitamin D3 plus a multivitamin in the prevention of cluster headache attacks.
Participants can be enrolled anywhere in the United States that has access to one of our participating labs (for blood work - anticipated to be available in most of the USA).
The study may include:
- Screening: Participants may be interviewed, examined, fill out surveys, and get blood testing
- Week 1: baseline period (no added medications - to establish a baseline)
- Weeks 2-4: double-blinded experimental period - participants receive either 1) high-dose Vitamin D3 + multivitamin, or 2) placebo + multivitamin. Participants also fill out a survey and have blood testing.
- Weeks 5-7: open-label period - ALL participants receive high-dose Vitamin D3 + multivitamin. Participants also fill out a survey and may have blood testing.
Specifically, our primary outcome is the change from baseline to experimental weeks 1-3 in the frequency of cluster headache attacks between placebo and high-dose vitamin D. Specific primary and secondary outcomes are listed below.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A diagnosis of episodic cluster headache according to the International Classification of Headache Disorders 3rd edition as well as cluster periods that are predictable and have a duration of 6 weeks or greater and approximately one attack daily minimum OR
- •A diagnosis of chronic cluster headache according to the International Classification of Headache Disorders 3rd edition as well as approximately one attack daily
- •Participants who are unlikely to need to change their preventive cluster headache treatment regimen in the next 6 weeks.
排除标准
- •Co-existing disease or other characteristic that precludes appropriate diagnosis of cluster headache.
- •Active drug or alcohol use or dependence that, in the opinion of the site investigator,would interfere with adherence to study requirements.
- •Inability or unwillingness of subject to give informed consent.
- •Known allergy to study drug, multivitamin, or placebo components
- •Pregnancy or lactation (breastfeeding)
- •Usage of greater than 4,000 International Units of Vitamin D3 daily within 60 days of the beginning of the study.
- •Concurrent use of Vitamin D and/or multivitamin along with the inability to stop them before the study begins.
- •Liver failure or known coagulation disorder (as this study includes vitamin K) such as haemophilia, von Willebrand disease, Factor V Leiden, Antithrombin III deficiency, Protein C or S deficiency, or anti-phospholipid antibody syndrome.
- •A personal medical history of more than 1 deep venous thrombosis and/or pulmonary embolism (as this study includes vitamin K).
- •Current use of anticoagulants (as this study includes vitamin K). Anticoagulants include: apixaban (Eliquis), betrixaban (Bevyxxa), dabigatran (Pradaxa), dalteparin (Fragmin), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, rivaroxiban (Xarelto), and warfarin (Coumadin).
- •Current use of medications that alter vitamin D metabolism, including steroids,interferon, phenytoin, phenobarbital, digitalis/digoxin, and thiazide diuretics (such as hydrochlorothiazide or chlorthalidone)
- •Participants who are aware that their most recent labwork in the last 2 years showed any of the following:
- •25-hydroxyvitamin D levels >75 nmol/L
- •Elevated calcium level
- •Elevated phosphate level
- •Abnormal parathyroid hormone levels
- •Elevated creatinine level
- •Of note if any values are outside the acceptable range for the study, candidates may still participate in the study if the most recent lab testing is inside the acceptable range for the study. For example, if a candididate were taking a vitamin or medication that may have caused these elevated levels, but no longer take the vitamin or medication, they may be enrolled if retesting is normal.
结局指标
主要结局
Change in average weekly frequency of cluster headache attacks
时间窗: (baseline, week 3)
Second primary outcome
次要结局
- Change in level of 25-hydroxyvitamin D(baseline, week 1)
- Change in average weekly frequency of cluster headache attacks((baseline, week 1))
- Number of participants who had a reduction of at least 50% in the weekly frequency of cluster headache attacks between baseline and week 6((baseline, week 6))
- Number of participants who had a reduction of at least 50% in the weekly frequency of cluster headache attacks between baseline and week 3((baseline, week 3))
- Number of participants who had a reduction of at least 30% in the weekly frequency of cluster headache attacks between baseline and week 3(baseline, week 3)
- Change in number of abortive medications or other treatments used per week(baseline, week 1)
- Change in intensity of cluster headache attacks as assessed by numerical rating scale(baseline, week 1)
- Change in number of participants whose disease is 'much better' or 'very much better' as assessed by the Patient Global Impression of Improvement Scale(baseline, week 1)
- Change in quality of life as measured by the Cluster Headache Quality of life questionnaire(baseline, week 1)
- Change in duration of cluster headache attacks, in minutes(baseline, week 1)
- Number of days until end of the cluster period after the start of treatment (i.e., the time to the end of an episodic cluster cycle)(upto 3 weeks from treatment)
- Change in level of calcium(baseline, week 1)
- Change in level of phosphate(baseline, week 2)
- Change in level of parathyroid hormone(baseline, week 2)
- Change in level of creatinine(baseline, week 2)
- Number of participants who had a reduction of at least 30% in the weekly frequency of cluster headache attacks between baseline and week 6(baseline, week 6)
研究者
Mark J Burish
Assistant Professor
The University of Texas Health Science Center, Houston
研究点 (2)
Loading locations...
相似试验
招募中
2 期
High-dose Vitamin D Supplement for the Prevention of Acute Asthma-like Symptoms in Preschool ChildrenAsthma in ChildrenNCT05043116Copenhagen Studies on Asthma in Childhood320
进行中（未招募）
3 期
High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving RemicadeUlcerative ColitisCrohn DiseaseIBDNCT03162432Boston Children's Hospital50
已完成
不适用
Efficacy and Safety of High Dose Vitamin D Supplementation for Overactive Bladder Dry in ChildrenOveractive BladderNCT05709990Xing Liu303
已完成
不适用
Vitamin D and Microbiota in Cystic FibrosisVitamin D DeficiencyCystic FibrosisNCT02589444Emory University41
已完成
不适用
Vitamin D and Resistance Exercise Training; Effects on Musculoskeletal Health in Frail Older Men and WomenSarcopeniaMuscle AtrophyOsteoporosisNCT02467153University of Birmingham19